Entries |
Document | Title | Date |
20100249016 | METAL-BINDING COMPOUNDS AND USES THEREFOR - The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further described in the application. The invention further provides a method of reducing the damage done by ROS to a cell, a tissue or an organ that has been removed from an animal. This method comprising contacting the cell, tissue or organ with a solution or medium containing an effective amount of a metal-binding compound of the invention. The invention further provides novel metal-binding compounds, pharmaceutical compositions comprising the metal-binding compounds, and kits comprising a container holding a metal-binding compound of the invention. | 09-30-2010 |
20100249017 | USE OF CNP-22, ALONE OR IN COMBINATION WITH PHYSALEMIN, AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 09-30-2010 |
20100249018 | COMPOSITION AND METHOD FOR PREVENTING AND TREATING IMMUNE-RELATED DISORDER - The present invention relates to an immunoregulating agent comprising a peptide, a pharmaceutical composition and a method of preventing or treating immune-related disorder such as sever sepsis or acute respiratory distress syndrome (ARDS), and the use of peptide for anti-inflammatory agent, an antibacterial agent, or an inhibiting agent of an immune cell apoptosis. | 09-30-2010 |
20100267615 | METHODS FOR TREATMENT AND/OR PREVENTION OF A DISEASE ASSOCIATED WITH VASCULAR LEAK - The present invention is directed to methods for treatment and/or prevention of a disease associated with vascular leak in a patient comprising administering to the patient an effective amount of SEQ ID NO: 1. | 10-21-2010 |
20100279922 | Melanocortin Receptor Ligands - The present invention is directed to compounds according to formula, | 11-04-2010 |
20100279923 | THERAPEUTIC APPLICATION OF KAZAL-TYPE SERINE PROTEASE INHIBITORS - The subject of the present invention is, in the most general aspect, the therapeutic application of the Kazal-type serine protease inhibitor Infestin or domains thereof or modified Kazal-type serine protease inhibitors based on Infestin homologs, which prevent the formation and/or stabilization of three-dimensional arterial or venous thrombi by interfering with proteins involved in activation of the so-called intrinsic coagulation pathway. In particular the present invention relates to the use of said Kazal-type serine protease inhibitors or fragments thereof or modified Kazal-type serine protease inhibitors, in the treatment or prophylaxis of a condition or disorder related to arterial thrombus formation, i. e. stroke or myocardial infarction, inflammation, complement activation, fibrinolysis, angiogenesis and/or diseases linked to pathological kinin formation such as hypotonic shock, edema including hereditary angioedema, bacterial infections, arthritis, pancreatitis, or articular gout, Disseminated Intravasal Coagulation (DIC) and sepsis. | 11-04-2010 |
20100279924 | PEPTIDES AND PEPTIDE DERIVATIVES AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - Therapeutic compositions can include modified peptides which are derived from the chain of the Bbeta(15-42)-fibrin fragment and wherein one or several of the amino acids of the sequence have been substituted by genetically encoded or not genetically encoded amino acids or peptidomimetics. They may exist as free peptides or as C-terminal derivative and/or being linked to a polyethylene glycol (PEG)-polymer, and have anti-inflammatory and/or endothelium stabilizing effects. Esters or amides may for instance be taken into consideration as C-terminal derivatives. Processes for production of the peptides and derivatives thereof are also described. | 11-04-2010 |
20100292131 | BIOMARKERS AND METHODS FOR DIAGNOSING, PREDICTING AND/OR PROGNOSING SEPSIS AND USES THEREOF - The present invention provides kits and methods for the diagnosis, prognosis and prediction of sepsis in a subject or for the differentiation between sepsis and SIRS in a subject, the method comprising(a) measuring the level of pro-hepcidin (pro-HEPC) in a biological sample taken from said subject, (b) measuring the level of at least one further biomarker selected from the group consisting of soluble TNF-receptor 2 (sTNFR2), Pentraxin-3 (PTX-3), Macrophage Colony-Stimulating Factor (MCSF), pro-Brain Natriuretic Protein (pro-BNP), one or more members of the Histone protein family, Procalcitonin (PCT) and c-Reactive Protein (CRP) in a biological sample from said subject, (c) using said measurements obtained in steps (a) and (b) to create a profile for said biomarkers and (d) comparing said profile with a reference biomarker profile obtained form a patient having SIRS or from a healthy subject. | 11-18-2010 |
20100317564 | IMMUNOREGULATORY PEPTIDES AND METHODS OF USE - Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media | 12-16-2010 |
20110053830 | METHODS FOR TREATING SEPTIC SHOCK - Methods for the treatment of septic shock are disclosed herein. The methods include the use of a therapeutically effective amount of inhibitory peptides that inhibit TLR activity. The peptides can be used with other agents for the treatment of septic shock. In one embodiment, a therapeutically effective amount of a peptide is administered to a subject with septic shock, such as septic shock induced by an infection with gram negative bacteria. | 03-03-2011 |
20110059885 | TREATMENT OF DISEASES AND CONDITIONS MEDIATED BY EICOSANOIDS - The method of the invention relates to an OmCI polypeptide or a polynucleotide encoding an OmCI polypeptide for the treatment of a disease or condition mediated by a leukotriene or hydroxyeicosanoid. | 03-10-2011 |
20110077190 | Selective Caspase Inhibitors and Uses Thereof - The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases). | 03-31-2011 |
20110082072 | Methods of Inhibiting Cell Death or Inflammation in a Mammal - In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal. | 04-07-2011 |
20110143992 | Methods and Compositions Related to GHS-R Antagonists - Disclosed herein are methods and compositions related to GHS-R antagonists. | 06-16-2011 |
20110143993 | ENDOTHELIAL BASEMENT MEMBRANE TARGETING PEPTIDE LIGANDS - Peptides that selectively bind to antigens exposed in vascular disease or dysfunction have been identified by biopanning a phage library. The ligands are useful when attached to a substrate to be in contact with endothelial surfaces, especially those where drug delivery is utilized, such as following angioplasty, with release from a drug delivery reservoir in a medical device such as a stent, or by administration intravenously in the form of nano or microparticles, although the peptides may also be used with other medical devices or substrates, for targeting or to increase adhesion to endothelial surfaces. The nanoparticle technology can be used to treat injured vasculature, a clinical problem of primary importance. The targeted nanoparticles are also useful in the treatment of other diseases and disorders such as oncologic and regenerative diseases and indications where neoangiogenesis is commonly observed. | 06-16-2011 |
20110152169 | SPARC ANTI-INFLAMMATORY ACTIVITY AND USES THEREOF - The invention provides methods of treating a mammal afflicted with an inflammatory disease, such as peritonitis, peritoneal adhesions or endometriosis, comprising the administration, intraperitoneal or otherwise, of a therapeutically effective amount of a SPARC polypeptide or a SPARC polypeptide-encoding isolated polynucleotide and a pharmacologic carrier. | 06-23-2011 |
20110152170 | Use of Procalcitonin (PCT) in Risk Stratification and Prognosis of Patients with a Primary, Non-Infectious Disease - Subject of the present invention are assays and in vitro methods for the in vitro diagnosis, prognosis and risk stratification of a patient having a primary, non-infectious disease, whereby the level of Procalcitonin (PCT) in a sample of a body fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition. | 06-23-2011 |
20110183886 | MELANOCORTIN RECEPTOR LIGANDS - The present invention is directed to compounds according to formula, | 07-28-2011 |
20110190194 | PREPARATION AND COMPOSITION OF INTER-ALPHA PROTEINS FROM BLOOD - The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (IαIp) and compositions thereof from blood. | 08-04-2011 |
20110190195 | MULTI-COMPONENT ANTIOXIDANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR REDUCING OR PREVENTING OXIDATIVE STRESS - An antioxidant compound is disclosed. The compound is characterized by (a) a peptide including at least three amino acid residues of which at least two are cysteine residues, each having a readily oxidizable sulfhydryl group for effecting antioxidation; and at least two peptide bonds, each being cleavable by at least one intracellular peptidase; and (b) a first hydrophobic or non-charged moiety being attached to an amino terminal of the peptide via a first bond and a second hydrophobic or non-charged moiety being attached to a carboxy terminal of the peptide via a second bond, the first hydrophobic or non-charged moiety and the second hydrophobic or non-charged moiety are selected so as to provide the antioxidant compound with membrane miscibility properties for permitting the antioxidant compound to cross cellular membranes; wherein cleavage of the at least two peptide bonds by the at least one intracellular peptidase results in generation of a plurality of antioxidant species, each including one of the cysteine residues having the readily oxidizable sulfhydryl group and which is also active in effecting antioxidation, thereby providing for a plurality of different antioxidant species acting in synergy in exerting antioxidation. | 08-04-2011 |
20110201542 | Myeloid Protein Activation of Anti-Inflammatory and Anti-Hypoxic Pathway - Provided are methods to enhance healing of wounds and tissue, especially during or pursuant to psychological and/or physical stress and to protect tissue from deleterious effects associated with oxidative, psychological and/or physical stress, including but not limited to extreme exertion, ischemia, infarct, and damage associated with reperfusion of ischemic or transplanted tissues. | 08-18-2011 |
20110237494 | USE OF PEPTIDIC VASOPRESSION RECEPTOR AGONISTS - The present invention relates to the use of novel compounds for the manufacture of a medicament for treatment of inter alia conditions associated with critical care as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds utilised are represented by the general formula (I), as further defined in the specification. | 09-29-2011 |
20110237495 | FUNCTIONAL METABOLOMICS COUPLED MICROFLUIDIC CHEMOTAXIS DEVICE AND IDENTIFICATION OF NOVEL CELL MEDIATORS - The invention relates to the use of microfluidic chemotaxis device to identify novel active compounds of the metabolome and methods to characterize their actions on cell motility. The invention also includes the active compounds of the metabolome identified by the methods and devices disclosed herein. The results from these in vitro experiments were then correlated with in vivo physiologic responses to identify the downstream effects and therapeutic value. Thus, the invention provides novel methods for treating or preventing second organ injury resulting from ischemia-reperfusion in a patient in need thereof The invention also provides methods of treating, preventing or ameliorating connective tissue degeneration in a patient in need thereof. The invention also provides methods of treating or preventing bone loss. In addition, the invention provides method for inducing bone regeneration in patients in need thereof or preventing bone loss in patients suspected to be in need thereof. | 09-29-2011 |
20110237496 | ANTINECROTIC ACTIVITY OF ALPHA 1-ANTITRYPSIN - The present invention is related to the use of alpha-1-antitrypsin as an anti-necrotic agent. This invention provides a method for the treatment of tissue necrosis by administration of alpha-1-antitrypsin. This invention further provides methods for prophylactic treatment of tissue necrosis and for inhibition of tissue necrosis in culture by addition of alpha-1-antitrypsin. | 09-29-2011 |
20110263482 | Complement inhibitors - The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases. | 10-27-2011 |
20110269666 | METHOD AND DRUG COMPOSITION FOR TREATING SEPTIC SHOCK HYPOTENSION - A method for treating septic hypotension, including administering at least one alpha-2 agonist or other sympatholytic, and at least one vasopressor. The alpha-2 agonist may be clonidine or dexmedetomidine, and the sympaholytic may be rilmelidine, monoxidine, alpha-methyldopa and alpha-methylparatyrosine. The vasopressor may be noradrenaline, adrenaline, vasopressin, angiotensin and phenylephrine. The method can include intravenous infusion of the patient with at least one inotrope such as dobutamine and phosphodiesterase inhibitors. Suitable inotropes include amrinone and milrinone. In a preferred embodiment, the alpha-2 agonist and the vasopressor are simultaneously administered. Also disclosed is a composition for treating septic shock hypotension which includes at least one alpha-2 agonist and at least one vasopressor. | 11-03-2011 |
20110288004 | Viral Sequences and Uses Thereof - The invention features polypeptide and polynucleotide sequences based on the 134R sequence. In some embodiments, these sequences include a heterologous signal sequence, such as the myxoma virus T7 signal sequence. The invention also features methods for treating immunological disorders and neoplasms (e.g., cancer) using the polypeptides and nucleotides described herein. Finally, the invention features fusion proteins including the myxoma virus T7 signal sequence. | 11-24-2011 |
20120015867 | THERAPEUTIC PEPTIDES AND METHOD - A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD. | 01-19-2012 |
20120046217 | TNF-alpha Antagonists Containing IGFBP5 - The present invention relates to: TNF-α antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-α antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and a method for screening a therapeutic agent for TNF-α overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNER1. | 02-23-2012 |
20120058933 | SYNTHETIC PEPTIDES AND PEPTIDE MIMETICS - The present invention provides Parotid Secretory Protein peptides, nucleic acids encoding the peptides, and methods of using the peptides, and methods of screening GL13 mimetics. | 03-08-2012 |
20120071394 | NOVEL POLYPEPTIDES AND USE THEREOF - The present invention provides a polypeptide having a biological activity of the Chemotaxis Inhibitory Protein of | 03-22-2012 |
20120077731 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, 1L-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides, to methods for preparing such amino acid sequences and polypeptides, to host cells expressing or capable of expressing such amino acid sequences or polypeptides, to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells, and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 03-29-2012 |
20120088715 | MUTATED ANTITHROMBINS, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS DRUGS - The present invention relates to the use of a composition including of at least a mutated antithrombin
| 04-12-2012 |
20120094893 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM - The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: | 04-19-2012 |
20120135916 | MONOMERIC AND DIMERIC FORMS OF ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE - Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed. | 05-31-2012 |
20120165244 | METHODS FOR BINDING LEWIS Y ANTIGEN - The present invention relates to a method for binding Lewis Y antigen of a subject, comprising administering to the subject an effective amount of N-terminal lectin-like domain of thrombomodulin (TMD1), or its analogues. | 06-28-2012 |
20120172285 | METHODS AND COMPOSITIONS FOR SPECIFIC MODULATION OF MCL-1 - A series of stapled BCL-2 family peptide helices were identified as able to target the survival protein MCL-I with high affinity and a subset with unprecedented selectivity. Agents and methods for selective pharmacologic neutralization of MCL-I are provided for drug discovery and therapeutic uses, including use in overcoming the apoptotic resistance of cancer and other diseases associated with impaired cell death. | 07-05-2012 |
20120178667 | METHODS FOR TREATING SEPTIC SHOCK - Methods for the treatment of septic shock are disclosed herein. The methods include the use of a therapeutically effective amount of inhibitory peptides that inhibit TLR activity. The peptides can be used with other agents for the treatment of septic shock. In one embodiment, a therapeutically effective amount of a peptide is administered to a subject with septic shock, such as septic shock induced by an infection with gram negative bacteria. | 07-12-2012 |
20120190610 | TETRANECTIN-APOLIPOPROTEIN A-I, LIPID PARTICLES CONTAINING IT AND ITS USE - A lipid particle comprising an apolipoprotein, a phosphatidylcholine and a lipid, such as a phospholipid, fatty acid or steroid lipid. In one embodiment the lipid particle comprises only one apolipoprotein. In one embodiment the lipid particle is consisting of one apolipoprotein, a phospholipid, a lipid, and a detergent. In one embodiment the lipid is a second phosphatidylcholine, wherein the first phosphatidylcholine and the second phosphatidylcholine differ in one or two fatty acid residues or fatty acid residue derivatives which are esterified to the glycerol backbone of the phosphatidylcholine. In one embodiment the apolipoprotein is selected from an apolipoprotein that has the amino acid sequence selected from SEQ ID NO: 01, 02, 06, 66, and 67, or is a variant thereof that has at least 70% sequence identity with the selected sequence. | 07-26-2012 |
20120196789 | PEPTIDE BASED PEROXIDASE INHIBITORS AND METHODS OF USING SAME - The present invention provides peptide-based peroxidase inhibitors having the formula AA | 08-02-2012 |
20120202733 | INHIBITION OF TREM RECEPTOR SIGNALING WITH PEPTIDE VARIANTS - Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices). | 08-09-2012 |
20120214729 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATION - The present invention relates to a composition containing Substance P for preventing or treating an inflammation. The composition containing Substance P according to the present invention exhibits the effect of decreasing leukocytes, neutrophils and hematopoietic stem cells in a blood, which are associated with the inflammation, and of increasing anti-inflammatory cytokines, regulatory T-lymphocytes, anti-inflammatory macrophages and the like, thereby terminating inflammatory response at an early stage, and is thus highly effective in preventing and treating the inflammation caused by a non-traumatic, traumatic, infectious or ischemic retinal injury. | 08-23-2012 |
20120277142 | MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME - Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases. | 11-01-2012 |
20120289452 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NECROSIS - A method for treating and/or preventing cell necrosis and diseases associated therewith, comprising the inhibition of one or more elastase enzymes within said cells. | 11-15-2012 |
20120302493 | Cyclic Peptides As G-Protein Coupled Receptor Antagonists - The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions. | 11-29-2012 |
20130005644 | CYCLIC AGONISTS AND ANTAGONISTS OF C5A RECEPTORS AND G PROTEIN-COUPLED RECEPTORS - The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions. | 01-03-2013 |
20130005645 | APOE PEPTIDE DIMERS AND USES THEREOF - The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed. | 01-03-2013 |
20130065816 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE - This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents. | 03-14-2013 |
20130079274 | PHARMACEUTICAL COMPOSITIONS FOR TREATING DYSREGULATED INFLAMMATORY DISEASES - In general, the present invention relates to a new use of lipopeptides or lipoprotein molecules, namely, for treating dysregulated inflammatory diseases. In particular, the present invention relates to pharmaceutical compositions for use in treating dysregulated inflammatory diseases including SIRS, MODS and sepsis. For example, the MALP-2 molecule allows to treat sepsis. | 03-28-2013 |
20130096048 | TREATMENT OF SEPSIS AND SEPTIC SHOCK USING GHRELIN AND GROWTH HORMONE - Methods are disclosed for treating sepsis and septic shock using a combination of ghrelin and growth hormone, and for using ghrelin to reduce organ and tissue injury and improve survival after combined radiation exposure and sepsis. | 04-18-2013 |
20130096049 | THERAPEUTIC CONJUGATES - The invention concerns a novel antimicrobial peptide (AMP) polymer conjugate comprising at least one AMP, typically colistin, and a dextrin polymer wherein said dextrin polymer has a molecular weight between 5,000-60,000 g/mol and is modified by the additions of pendant groups which increase the stability of the conjugate and so delays its degradation thereby slowing the rate at which the AMP is released. | 04-18-2013 |
20130109614 | ANTAGONISTS FOR DISEASES INDUCED BY CELLS WITH HIGH-AFFINITY ELR-CXC CHEMOKINE RECEPTOR PROTEINS | 05-02-2013 |
20130109615 | METHODS FOR INHIBITING NECROSIS | 05-02-2013 |
20130150282 | LTBP2 AS A BIOMARKER FOR EVALUATING THE RISK OF DEATH IN A DISEASED SUBJECT - The application discloses methods for treating a subject presenting with one or more signs of an inflammatory condition, or methods for evaluating the risk of death within a year for a subject presenting with one or more signs of an inflammatory condition, based on measuring the quantity of LTBP2 in a sample from the subject; and kits and devices for measuring LTBP2 and/or performing said methods. | 06-13-2013 |
20130150283 | SHORT PEPTIDES USEFUL FOR TREATMENT OF ISCHEMIA/REPERFUSION INJURY AND OTHER TISSUE DAMAGE CONDITIONS ASSOCIATED WITH NITRIC OXIDE AND ITS REACTIVE SPECIES - This invention discloses isolated short peptides comprising the amino acid sequence Cys-Glu-Phe-His (CEFH; SEQ ID NOS: 1 and 15) and analogs thereof as well as compositions comprising CEFH peptides and analogs thereof. The CEFH peptides disclosed herein are effective in mediating the denitration of 3-nitrotyrosines (3-NT) in cellular proteins thereby preventing tissue damage associated with excess nitric oxide (NO) and its reactive species. The CEFH peptides disclosed herein are useful in the treatment of ischemia/reperfusion (I/R) injury and other disorders. | 06-13-2013 |
20130157928 | NOCICEPTIN MIMETICS - The present invention relates to nociceptin peptide mimetics that have α-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogues which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described. | 06-20-2013 |
20130172231 | COMPOSITION FOR TREATING SEPSIS OR SEPTIC SHOCK COMPRISING THE PEPTIDE ORIGINATED FROM THE SMAD6 - Disclosed is a pharmaceutical composition comprising a Smad6-derived peptide as an active ingredient. Having ability to specifically bind to Pellino-1, the Smad6-derived peptide is effectively useful in the treatment of the sepsis mediated by excessively activated TLR. The peptide effectively reduces the expression of inflammatory cytokines, protects cells from sepsis-induced apoptosis, and exhibits high bacterial clearance in animal models of sepsis. | 07-04-2013 |
20130178412 | DIHYDROXYPROPLY-CYSTEINE PEPTIDE AND AGENT CONTAINING THIS PEPTIDE - The invention relates to a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids bonded in the form of esters at the dihydroxypropyl group, and which has the following sequence: | 07-11-2013 |
20130203648 | Preparation of Recombinant Human Plasma Phospholipid Transfer Protein (PLTP) From the Milk of Transgenic Animals - The invention relates to obtaining a preparation of recombinant human PLTP from the milk of a transgenic animal containing in its genome one or more copies of a transgene comprising a polynucleotide coding for human PTLP, placed under transcriptional control of a promoter permitting its specific expression in the cells of the mammary glands of said animal. The recombinant human PLTP preparation obtained can be used in the prevention or treatment of septic shock. | 08-08-2013 |
20130203649 | INHIBITORS OF TLR SIGNALING BY TARGETING TIR DOMAIN INTERFACES - TIR-domain decoy peptides and TIR domain peptides are disclosed, as well as methods of using the peptides in the regulation of toll-like receptor (TLR) activation and signaling. | 08-08-2013 |
20130203650 | POLYPEPTIDES DERIVED FROM ALPHA-1 ANTITRYPSIN AND METHODS OF USE THEREOF - The present invention relates to isolated polypeptides comprising the amino acid sequence of residues 378-413 of | 08-08-2013 |
20130217616 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION - The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides. | 08-22-2013 |
20130225477 | Oral Lactoferrin in the Treatment of Severe Sepsis - The present invention relates to lactoferrin for use in the treatment of severe sepsis. In particular, the present invention relates to methods of effectively treating sepsis, in particular, severe sepsis, by administering orally a composition of lactoferrin (LF). More particularly, the present invention relates to methods of treating prophylactically or therapeutically sepsis, in particular, severe sepsis, by administering orally a composition of lactoferrin to patients with an APACHE II score ≦25, in particular <25. | 08-29-2013 |
20130225478 | PEPTIDES BASED ON THE TRANSMEMBRANE DOMAIN OF A TOLL-LIKE RECEPTOR (TLR) FOR TREATMENT OF TLR-MEDIATED DISEASES - Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease. | 08-29-2013 |
20130225479 | Methods and Compositions for Treating Inflammation - The present invention provides methods and compositions for treating inflammation and inflammatory disorders in a subject, by administering an effective amount of KSHV-Orf63 and/or active peptides and/or fragments thereof. | 08-29-2013 |
20130231273 | SHORTENED TETRANECTIN-APOLIPOPROTEIN A-1 FUSION PROTEIN, A LIPID PARTICLE CONTAINING IT, AND USES THEREOF - Herein is reported a shortened tetranectin-apolipoprotein A-I fusion protein and a lipid particle comprising the shortened tetranectin-apolipoprotein A-I fusion protein as well as uses thereof. | 09-05-2013 |
20130244926 | MEDICAMENT FOR THERAPEUTIC TREATMENT AND/OR IMPROVEMENT OF SEPSIS - A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient. | 09-19-2013 |
20130252878 | COMPOSITION CONTAINING PEPTIDE LIGAND THAT BONDS WITH CXCR2 FOR TREATING INFECTIVE AND INFLAMMATORY DISEASES - A therapeutic agent for treating an infectious or inflammatory disease, a pharmaceutical composition for treating an infectious or inflammatory disease, and a method of using a pharmaceutical composition are provided. The pharmaceutical composition includes a peptide ligand that binds with CXCR2 as an active component. The active component can be useful in preventing and treating infectious and/or inflammatory diseases, including sepsis and septic shock by promoting the removal of bacteria by phagocytosis, suppressing an inflammatory response, and suppressing the apoptosis of immune cells. | 09-26-2013 |
20130296223 | USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS - The present invention provides methods for preventing, treating, or reducing the severity of sepsis, severe sepsis or septic shock, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen. In certain embodiments, the alpha thymosin peptide regimen is scheduled or timed with respect to potential, expected and/or diagnosed sepsis, severe sepsis or septic shock. In certain embodiments, the patient is immunodeficient or immunecompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide peptide helps to protect the patient from, or reduce the severity of, sepsis, severe sepsis or septic shock. | 11-07-2013 |
20140005096 | METHODS OF TREATING INFLAMMATION | 01-02-2014 |
20140057829 | Citrullinated Histone H3 (Cit H3) in Septic Shock - Methods of diagnosing sepsis, severe sepsis, or septic shock and predicting prognosis in subjects with septic shock, based on levels of citrullinated histone H3 (Cit H3) in the subject, e.g., in a sample comprising serum (e.g., whole blood, serum, or plasma), cerebrospinal fluid, urine, saliva, or peritoneal fluid from the subject. | 02-27-2014 |
20140073555 | USE OF MULTIVALENT SYNTHETIC LIGANDS OF SURFACE NUCLEOLIN FOR TREATING CANCER OR INFLAMMATION - A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising a support on which at least 3 pseudopeptide units are grafted, said compound being of formula (I). | 03-13-2014 |
20140121153 | NOVEL POLYPEPTIDES - The present invention relates to an isolated polypeptide comprising (a) the amino acid sequence set forth in SEQ ID NO: 21; or (b) an amino acid sequence that is at least 95% identical to SEQ ID NO: 21, and to therapeutic treatments based thereon. | 05-01-2014 |
20140194342 | Peptide-Based Peroxidase Inhibitors and Methods of Using Same - The present invention provides peptide-based peroxidase inhibitors having the formula AA | 07-10-2014 |
20140194343 | CTRP6 WHICH CAN BE USED AS THERAPEUTIC AND PROPHYLACTIC AGENT FOR AUTOIMMUNE DISEASES - [Problem] The topic of the present invention is the elucidation of the biological function of CTRP6 and its application. | 07-10-2014 |
20140206598 | MOLECULE FOR TREATING AN INFLAMMATORY DISORDER - The invention provides a L19 source as a medicament, preferably for preventing or treating an inflammatory disorder in an individual. | 07-24-2014 |
20140249072 | COMPLEMENT FACTOR B ANALOGS AND THEIR USES - The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway. | 09-04-2014 |
20140287985 | NOVEL USES OF ELAFIN - The invention relates to novel uses of the polypeptide elafin, and/or homologues, derivatives or fragments thereof having inhibitory activity against leukocyte elastase for the prevention and treatment of medical conditions like SIRS. | 09-25-2014 |
20140287986 | TEMPLATE-FIXED PEPTIDOMIMETICS AS INHIBITORS OF FPR1 - Novel template-fixed β-hairpin peptidomimetics of the general formula (I): cyclo[P | 09-25-2014 |
20140309158 | COMPOSITIONS AND METHODS FOR IMMUNOMODULATION - The invention relates to methods and reagents for the treatment of immunological diseases. In particular, the invention relates to isoforms of the C4b-binding protein (C4BP) lacking beta chains as well as to fragments and peptides derived thereof and to the uses of these polypeptides for the treatment of immunological diseases such as immunoinflammatory disease, sepsis, an autoimmune disease, transplant rejection, graft-versus-host disease and a hypersensitivity disease. Moreover, the invention relates also the use of factor H for the treatment of immunological diseases. In addition, the invention relates to tolerogenic dendritic cells obtained using the C4BP isoform lacking beta chain, the peptides and fragments thereof and factor H and to the therapeutic uses of said cells. | 10-16-2014 |
20140315785 | METHODS RELATED TO THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY CONDITIONS - The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan. | 10-23-2014 |
20140323389 | METHODS FOR PREVENTING OR TREATING DISORDERS BY INCREASING BIOAVAILABILITY OF IRON AND RELATED PHARMACEUTICAL FORMULATION - The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition to a subject in need thereof, which composition contains a lipocalin mutein or a fragment or a variant thereof capable of increasing the bioavailability of iron in the subject. | 10-30-2014 |
20140336104 | ACTH PROPHYLACTIC TREATMENT OF RENAL DISORDERS - Provided herein are methods for prophylactic treatment of renal disorders comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing a renal disorder | 11-13-2014 |
20140336105 | Anti-Inflammatory Peptides And Use Thereof - Anti-inflammatory peptides and pharmaceutical compositions including lysine, alanine, leucine and/or valine for treating inflammatory conditions and uses thereof. Anti-inflammatory peptides for treating IgE-mediated allergies and inflammatory conditions caused by a microbial infection including but not limited to sepsis. | 11-13-2014 |
20150011458 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF - The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases). | 01-08-2015 |
20150011459 | SHORTENED TETRANECTIN-APOLIPOPROTEIN A-1 FUSION PROTEIN, A LIPID PARTICLE CONTAINING IT, AND USES THEREOF - Herein is reported a shortened tetranectin-apolipoprotein A-I fusion protein and a lipid particle comprising the shortened tetranectin-apolipoprotein A-I fusion protein as well as uses thereof. | 01-08-2015 |
20150024994 | USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS - The present invention provides methods for preventing, treating, or reducing the severity of sepsis, severe sepsis or septic shock, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen. In certain embodiments, the alpha thymosin peptide regimen is scheduled or timed with respect to potential, expected and/or diagnosed sepsis, severe sepsis or septic shock. In certain embodiments, the patient is immunodeficient or immunocompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide helps to protect the patient from, or reduce the severity of, sepsis, severe sepsis or septic shock. | 01-22-2015 |
20150031598 | NEMO BINDING DOMAIN FUSION PROTEINS - Novel fusion proteins compromising nuclear factor kB essential modulator-binding (NEMO) domain or a fragment thereof and MCoTI-I/II or a fragment thereof, and their use for the treatment of inflammatory diseases and other medical conditions. | 01-29-2015 |
20150045283 | Protease Activated Receptor-1 (PAR1) Derived Cytoprotective Polypeptides and Related Methods - The present invention provides novel PAR lderived cytoprotective oligopeptides or polypeptides which typically contain at least the first 4 N-terminal residues that are substantially identical to the corresponding N-terminal residues of Met | 02-12-2015 |
20150065414 | MODIFIED TOLL-LIKE RECEPTOR 2 (TLR2) LIGANDS AS INHIBITORS OF NEUTROPHIL RECRUITMENT - The present invention provides modified TLR2 ligands useful for modulating inflammatory responses. In particular, the ligands comprise (a) a fatty acid di- or tri-linoleate and (b) a GM1-binding peptide. The linoleate provides the anti-inflammtory function, while the GM1-binding peptide facilitates endocytosis. | 03-05-2015 |
20150080288 | NITRATION SHIELDING PEPTIDES AND METHODS OF USE THEREOF - Nitration shielding peptides that reduce or prevent nitration of a protein of interest are disclosed. The peptide can serve as molecular sink for nitrating agents, block access of the nitrating agents to the target tyrosine on the protein of interest, serve as substrate for the nitrating agent (i.e., provide an alternative nitratable tyrosine residue), provide a nitrating agent neutralizing moiety such as antioxidant, or a combination thereof. The nitration shielding peptide can be a fusion protein that includes one or more additional domains such a protein transduction domain, a targeting signal, a purification tag, or any combination thereof. Exemplary nitration shielding peptides for reducing nitration of RhoA and PKG-1α, and methods of use thereof for treating pathologies, disease, and disorders associated with nitration of RhoA and PKG-1α, respectively are also provided. | 03-19-2015 |
20150099691 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF - A dipeptide derivative as formyl peptide receptor 1 (FPR1) antagonist is provided. The dipeptide derivative is represented by formula (I), | 04-09-2015 |
20150126432 | V1a Receptor Agonists - Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites. | 05-07-2015 |
20150141322 | THERAPEUTIC AGENT, TREATMENT METHOD AND INSPECTION METHOD FOR DISEASES CAUSED BY ACTIVATION OR NEUTROPHILS - The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a neutrophil activation regulator which comprising a histidine-rich glycoprotein (HRG) as an active ingredient, and provides a therapeutic agent for diseases caused by neutrophil activation comprising the neutrophil activation regulator, a treatment method for diseases caused by neutrophil activation, and further an inspection method for diseases caused by neutrophil activation. The present invention is based on the neutrophil activation regulator including the HRG as an active ingredient. The present invention extends to the depressant agent for neutrophil-vascular endothelial cell interaction including the HRG of the present invention as an active ingredient, the treatment method for diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation. The present invention also extends to the inspection method for inflammatory diseases accompanied by neutrophil activation by measuring the blood HRG level. | 05-21-2015 |
20150297671 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) - The present invention relates to peptide analogues comprising one or more branched amino acid probes and a peptide, native or variants thereof. | 10-22-2015 |
20150307572 | BIOACTIVE PEPTIDES AND METHODS OF USING SAME - Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation. | 10-29-2015 |
20150322125 | NOVEL IL-17A BINDING MOLECULES AND MEDICAL USES THEREOF - The present invention relates to a polypeptide inhibiting the activity of glycosylated IL-17A, wherein the polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X | 11-12-2015 |
20150366930 | TREATMENT OF DISORDERS WITH ALTERED VASCULAR BARRIER FUNCTION - The present invention provides methods of using RASIP1 agonists and antagonists to modulate vascular barrier function and regulate new vessel formation, and to treat related disorders. | 12-24-2015 |
20160015773 | INHIBITING PEPTIDES DERIVED FROM TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF - The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis. | 01-21-2016 |
20160030506 | COMBINATION COMPRISING ZIDOVUDINE AND POLYMYXIN - The present invention relates to the use of a combination of an anti-retroviral agent such as zidovudine and an anti-microbial agent for killing clinically latent microorganisms associated with microbial infections and to novel combinations comprising an anti-retroviral agent such as zidovudine and an anti-microbial agent for the treatment of microbial infections. | 02-04-2016 |
20160030516 | PREVENTION, THERAPY AND PROGNOSIS/MONITORING IN SEPSIS AND SEPTIC SHOCK - The invention relates to the use of a peptide which binds to lipopolysaccharide (LPS) or lipoteichoic acid (LTA), for manufacturing a pharmaceutical composition for treating sepsis or septic shock, wherein the peptide comprises the amino acid sequence of apolipoprotein CI (apoCI) or a part thereof that comprises at least the amino acids of the C-terminal helix of apoCI. The use of human apoCI is preferred. The peptide can be administered clinically to patients who have sepsis or threaten to develop sepsis. Measurement of the apoCI content in blood can be utilized for determining the severity and prognosis of the course of the septic condition or for monitoring an anti-sepsis treatment. | 02-04-2016 |
20160045572 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME - This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived. | 02-18-2016 |
20160047817 | LTBP2 AS A BIOMARKER FOR EVALUATING THE RISK OF DEATH IN A DISEASED SUBJECT - The application discloses methods for treating a subject presenting with one or more signs of an inflammatory condition, or methods for evaluating the risk of death within a year for a subject presenting with one or more signs of an inflammatory condition, based on measuring the quantity of LTBP2 in a sample from the subject; and kits and devices for measuring LTBP2 and/or performing said methods. | 02-18-2016 |
20160074465 | Methods for Treating Hypotension - The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension. | 03-17-2016 |
20160082119 | SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE - Described herein are methods and compositions for intracellular delivery of therapeutic molecules. Disclosed herein are selective delivery conjugate comprising a targeting ligand conjugated to a selective delivery molecule (a) an acidic sequence (portion of A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or retention sequence (portion of B), and (c) a linker between portion of A and portion of B, and (d) at least one cargo moiety. Also, described are selective delivery molecules comprising a second linker comprising an intracellular cleavage site and optionally a self-immolative cleavage site. | 03-24-2016 |
20160083429 | COMPOSITIONS AND METHODS FOR ENDOTOXIN NEUTRALIZATION - Peptide therapeutic agents are provided that bind to lipid A and neutralize the injurious effects of endotoxin. | 03-24-2016 |
20160145318 | PREPARATION AND COMPOSITION OF INTER-ALPHA INHIBITOR PROTEINS FROM BLOOD - The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (IαIp) and compositions thereof from blood. | 05-26-2016 |
20160175386 | Immunomodulators | 06-23-2016 |
20160175387 | Use of Immune Suppressive Domains as Medicaments | 06-23-2016 |
20160176925 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | 06-23-2016 |
20160176929 | BRADYKININ RECEPTOR MODULATORS AND USE THEREOF | 06-23-2016 |
20160193288 | THERAPEUTIC TREM-1 PEPTIDES | 07-07-2016 |
20160194365 | METHODS FOR TREATMENT OF AND PROPHYLAXIS AGAINST INFLAMMATORY DISORDERS | 07-07-2016 |
20160200783 | USE OF MULTIVALENT SYNTHETIC LIGANDS OF SURFACE NUCLEOLIN FOR TREATING CANCER OR INFLAMMATION | 07-14-2016 |
20170231935 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH | 08-17-2017 |
20110224141 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER - A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed. | 09-15-2011 |
20110245172 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS - The present invention relates to biocompatible oligomer-polymer compositions for the in situ formation of implants, wherein the implants release a bioactive agent, a metabolite, or a prodrug thereof, at a controlled rate. The sustained release delivery system includes a flowable composition containing a bioactive agent, a metabolite, or a prodrug thereof, and an implant containing a bioactive agent, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, a biocompatible end-capped oligomeric liquid, and a bioactive agent, a metabolite, or a prodrug thereof. | 10-06-2011 |
20110312889 | SUSTAINED RELEASE OF MICROCRYSTALLINE PEPTIDE SUSPENSIONS - The invention relates to a fluid, milky microcrystalline aqueous suspension of a peptide or peptidomimetic and a counter-ion of a strong proton donor in water, wherein the peptide or peptidomimetic and counter-ion are present in amounts and at a molar ratio sufficient to form the suspension upon mixing and without formation of a gel. The invention also relates to lyophilized compositions that include a dried suspension, methods of making the lyophilized composition, methods of preparing the suspension, and sustained release formulations prepared by the methods. | 12-22-2011 |
20130288968 | LEUPROLIDE INJECTION - The present invention provides a sterile solution comprising leuprolide acetate in a pharmaceutically acceptable vehicle, wherein solution is present as a reservoir in a multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the said reservoir in a single daily dose and further being adapted to provide multiple portions of solution said while the reservoir remains sterile. | 10-31-2013 |
20140024591 | Methods For Characterizing And Isolating Circulating Tumor Cell Subpopulations - Provided are methods and assays for cancer cell classification, cancer prognosis and treatment based on the isolation of circulating tumor cells and the characterization of their nuclear organization and telomere signatures. | 01-23-2014 |
20140088011 | Softgel of NLKJ for treating prostate diseases - A softgel of NLKJ for the treatment of prostate diseases, comprising 0.05-1.0 g of NLKJ and 0.05-1.5 mg of an antioxidant, said NLKJ having the following physicochemical parameter: acid value<0.56, iodine value 95.0-107.00, saponification value 185.00-195.00, specific gravity 0.914-0.918 (20° C.), and refractive index 1.470-1.475 (20° C.). The inhibition of the softgel of NLKJ on the growth of prostate cancer in combination with the injection of Lupron is stronger than that of each of them used alone. | 03-27-2014 |
20150080305 | APPLICATION OF INITIAL DOSES OF LHRH ANALOGUES AND MAINTENANCE DOSES OF LHRH ANTAGONISTS FOR THE TREATMENT OF HORMONE-DEPENDENT CANCERS AND CORRESPONDING PHARMACEUTICAL KITS - LHRH analogues and LHRH antagonists for use in the treatment or prophylaxis of hormone-dependent cancers, in particular prostate cancer, prostate carcinoma and/or advanced prostate carcinoma, by administering an initial dose of an LHRH analogue over a first period sufficient to effect hormonal castration, then administering a maintenance dose of an LHRH antagonist over a second period, the dose being insufficient to achieve and/or maintain hormonal castration. | 03-19-2015 |
20150335700 | RECOVERY AND PROCESSING OF HUMAN EMBRYOS FORMED IN VIVO - A kit having instructions for use for performing uterine lavage in a female patient includes a uterine lavage catheter configured for insertion into a woman's uterus to remove viable blastocysts from the uterus, and one or more first containers having a sufficient dosage amount of a GnRH antagonist to cause desynchronization of the endometrium of the patient prior to, during and/or following recovery of viable blastocysts from the uterus. | 11-26-2015 |
20150352060 | NOVEL TREATMENT OF PROSTATE CARCINOMA - Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer. | 12-10-2015 |
20160022635 | USE OF ARGININE VASOPRESSIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PROSTATE CANCER - Described herein are methods of decreasing the proliferation of prostate cancer cells in a mammalian subject by administering to a subject in need thereof a composition comprising an AVPR antagonist in amount effective to decrease proliferation of the cancer cells. Also provided are methods of inducing prostate cancer cell death (or decreasing invasion migration of the prostate cancer cells) in a mammalian subject by administering to a subject in need thereof a composition comprising an AVPR antagonist. | 01-28-2016 |
20160106804 | Pharmaceutical composition with improved stability - The present invention provides an injectable composition for controlled release drug delivery and the process of making the same, where the composition comprises: a lactate-based polymer having a weight average molecular weight between 5,000 and 50,000 dalton, an acid number of less than 3 mgKOH/g and the content of residual lactide monomers in the lactate-based polymer of less than about 0.3% by weight; a pharmaceutically acceptable organic solvent; and a bioactive substance or a salt thereof that contains an amino acid serine in the molecular structure that is capable of reacting with lactide monomer to form a conjugate; and where the composition reduces the formation of the conjugate. | 04-21-2016 |
20160106847 | LOW-BURST POLYMERS AND METHODS TO PRODUCE POLYMER - A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use. | 04-21-2016 |